Rubitecan

Drug Profile

Rubitecan

Alternative Names: 9-NC; 9-Nitro-20(S)-camptothecin; 9-Nitro-camptothecin; Partaject Orathecin; Partaject rubitecan; RFS 2000

Latest Information Update: 14 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Stehlin Foundation for Cancer Research
  • Developer SuperGen
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections; Pancreatic cancer

Highest Development Phases

  • Discontinued Breast cancer; Chronic myelomonocytic leukaemia; Colorectal cancer; HIV infections; Leukaemia; Lung cancer; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 26 Apr 2006 Interim results from a US-based phase II clinical trial in patients with primary advanced Pancreatic cancer have been added to the Cancer therapeutic trials section
  • 24 Jan 2006 SuperGen has withdrawn its MAA from the EMEA for rubitecan for the treatment of Pancreatic cancer
  • 20 Jan 2006 Phase-III clinical trials in Pancreatic cancer in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top